Owner Scorecard


← All companies ← STNG Manual SU → ← STE Medical Devices & Equipment SYK →

STVN, Stevanato Group S.p.A.

Medical Devices & Equipment capital-intensive Capital build-out

Revenue is Biopharmaceutical and Diagnostic Solutions (88%) and Engineering (12%).

Latest annual: FY2025 20-F · figures as filed, in EUR
STVN · Stevanato Group S.p.A.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
€1.2B
+7.4% YoY · 12% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue €1.2B 5-yr avg €1.0B
Gross margin 29% 5-yr avg 30%
Operating margin 16.8% 5-yr avg 17.7%
ROIC 11% 5-yr avg 17%
Owner-earnings margin 17% 5-yr avg 8%
Free cash flow margin 2% 5-yr avg −10%

The business in brief

What this business is and what moves its needle, from its own SEC filings.

What it is
A medical-device business, placing equipment that pulls consumables and service behind it.
Situation
Capital build-out. Capital spending has surged to 22% of sales, today's earnings are charged less depreciation than tomorrow's will be.
What moves the needle
Gross margin has run about 29% and operating margin about 17% through the cycle, a solid spread between what it charges and what the product costs to make. Capital spending runs about 22% of sales, well above depreciation, so the return earned on what it sinks into that plant weighs as much as the margin. Read this kind of business on the installed base and what follows it.
Is it a good business?
Return on capital has run in the teens (median 19%, above 15% in 4 of 7 years). Owner earnings agree: roughly 7% of revenue reaches owners as cash, consistently. Returns like these are solid but short of clear franchise economics; whether they hold is what the 10-K settles, not the multiple.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 20-F →

Biopharmaceutical And Diagnostic Solutions is 88% of revenue, with Engineering the other meaningful segment at 12%.

Revenue by reportable segment, FY2025
  • Biopharmaceutical And Diagnostic Solutions88%€1.0B
  • Engineering12%€148M
By geographyEMEA58%North America31%Asia Pacific9%Italy8%South America3%

From the segment footnote of the company's own 20-F. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2019–2025

realized figures from each filing · older years to the left
2019’192020’202021’212022’222023’232024’242025’25TTMTTMDec 2025
Income statement
€537M€662M€844M€984M€1.1B€1.1B€1.2B€1.2BRevenueRevenue
26%29%31%33%31%27%29%29%Gross marginGross mgn
€62M€103M€162M€192M€201M€161M€199M€199MOperating incomeOp. inc.
11.6%15.6%19.2%19.6%18.5%14.6%16.8%16.8%Operating marginOp. mgn
€39M€79M€134M€143M€146M€118M€140M€140MNet incomeNet inc.
29%18%19%24%23%27%26%26%Effective tax rateTax rate
Cash flow & returns
€43M€156M€133M€103M€105M€156M€286M€286MOperating cash flowOp. cash
€46M€54M€56M€65M€78M€81M€89M€78MDepreciationDeprec.
(€43M)€23M(€57M)(€104M)(€119M)(€43M)€58M€68MWorking capital & otherWC & other
€68M€90M€108M€235M€433M€303M€264M€264MCapexCapex
12.7%13.5%12.8%23.9%39.9%27.4%22.2%22.2%Capex / revenueCapex/rev
(€4M)€102M€77M€38M€27M€75M€198M€208MOwner earningsOwner earn.
−0.7%15.3%9.1%3.9%2.5%6.8%16.6%17.5%Owner earnings marginOE mgn
(€26M)€66M€26M(€132M)(€328M)(€147M)€22M€22MFree cash flowFCF
−4.8%10.0%3.0%−13.4%−30.2%−13.3%1.9%1.9%Free cash flow marginFCF mgn
€6M€9M€11M€14M€14M€14M€15M€15MDividends paidDiv. paid
25%43%31%19%15%9%11%11%ROICROIC
15%25%16%14%13%8%9%9%Return on equityROE
12%22%15%13%12%7%8%8%Retained to equityRetained/eq
Balance sheet
€85M€157M€438M€262M€74M€100M€141M€141MCash & investmentsCash+inv
€128M€165M€213M€302M€296M€303M€303MReceivablesReceiv.
€139M€149M€213M€255M€245M€268M€268MInventoryInvent.
€163M€231M€309M€354M€298M€342M€342MAccounts payablePayables
€104M€84M€117M€203M€243M€229M€229MOperating working capitalOper. WC
€493M€866M€846M€862M€880M€943M€943MCurrent assetsCur. assets
€316M€339M€463M€574M€477M€536M€536MCurrent liabilitiesCur. liab.
1.6×2.6×1.8×1.5×1.8×1.8×1.8×Current ratioCurr. ratio
€47M€47M€47M€50M€50M€50M€50MGoodwillGoodwill
€968M€1.4B€1.7B€2.1B€2.3B€2.5B€2.5BTotal assetsAssets
(€85M)(€157M)(€438M)(€262M)(€74M)(€100M)(€141M)(€141M)Net debt / (cash)Net debt
4.1×4.7×8.6×6.4×11.2×11.2×8.8×8.8×Interest coverageInt. cov.
€265M€310M€842M€996M€1.1B€1.4B€1.5B€1.5BShareholders’ equityEquity
Per share
241M241M253M265M265M271M273M273MShares out (diluted)Shares
€2.23€2.75€3.34€3.72€4.10€4.07€4.35€4.35Revenue / shareRev/sh
€0.16€0.33€0.53€0.54€0.55€0.43€0.51€0.51EPS (diluted)EPS
€-0.02€0.42€0.30€0.15€0.10€0.28€0.72€0.76Owner earnings / shareOE/sh
€-0.11€0.27€0.10€-0.50€-1.24€-0.54€0.08€0.08Free cash flow / shareFCF/sh
€0.03€0.04€0.04€0.05€0.05€0.05€0.05€0.05Dividends / shareDiv/sh
€0.28€0.37€0.43€0.89€1.64€1.12€0.97€0.97Cap. spending / shareCapex/sh
€1.10€1.29€3.33€3.76€4.27€5.18€5.45€5.45Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
6-yr5-yr
Revenue / share+11.8%/yr+9.6%/yr
Owner earnings / share+11.4%/yr
EPS+21.0%/yr+9.4%/yr
Dividends / share+13.2%/yr+7.8%/yr
Capital spending / share+22.7%/yr+21.0%/yr
Book value / share+30.5%/yr+33.4%/yr

The record, charted

FY2019–2025

Each measure over its full record; the current point and the worst year marked.

Share count
273Mpeak FY2025
ROIC
11%low FY2024
Gross margin
29%low FY2019

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

€198Mowner earningsvs.€140Mnet incomelow FY2019

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetained

Each year's operating cash, by what management did with it: the mix, and how it drifts.

FY2019FY2025

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business earned €198M of owner earnings, the operating cash left after the €89M it takes just to hold its position. It put €175M more into growth; free cash flow, after that spending, was €22M.

Reported net income€140M
Owner earnings€198M · 17% of revenue
FY2025FY2024FY2023FY2022FY2021
Reported net income€140M€118M€146M€143M€134M
Depreciation & amortizationnon-cash charge added back+€89M+€81M+€78M+€65M+€56M
Working capital & othertiming of cash in and out, other non-cash items+€58M−€43M−€119M−€104M−€57M
Cash from operations€286M€156M€105M€103M€133M
Maintenance capital expenditurethe spending needed just to hold position and volume−€89M−€81M−€78M−€65M−€56M
Owner earnings€198M€75M€27M€38M€77M
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−€175M−€222M−€355M−€170M−€51M
Free cash flow€22M(€147M)(€328M)(€132M)€26M
Owner-earnings marginowner earnings ÷ revenue17%7%2%4%9%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the maintenance capital it must spend to hold its position (here about €89M, roughly its depreciation, the rate its assets wear out). The other €175M of its capital spending is growth it chose, not upkeep it owed; charged only with the maintenance it must do, the business earns well more than the year's free cash flow shows.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 20-F · source on SEC EDGAR →

Will it survive?

  • Comfortable
    Operating income €199M ÷ interest expense €23M
    What this means

    Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.

  • Net cash, debt-free
    Cash €131M + ST investments €11M − debt €0
    What this means

    Cash and short-term investments exceed every dollar of debt by €141M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 93 + DIO 116 − DPO 148 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Not enough data
    Industry peers: median 6%
    What this means

    The filing data didn't include the inputs for this check.

  • Solid through the cycle
    7-yr median margin, range -1%–17%; latest €208M = operating cash €286M − maintenance capex €78M
    Industry peers: median 7%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 17% of revenue this year, a 7% median across 7 years. It chose to put €185M more into growth, so free cash flow this year was €22M — the gap is investment, not weakness.

  • Cash-backed
    Cash from ops €286M ÷ net income €140M
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Reinvests most of it
    Dividends + buybacks €15M ÷ Owner Earnings €208M
    What this means

    Of €208M Owner Earnings, €15M (7%) went back to shareholders, €15M dividends, €0 buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting? 3.36×
    Expanding
    Capex €264M ÷ depreciation €78M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 3 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size
    Revenue ≥ $2B (a dollar floor) · €1.2B
    What this means

    Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.

  • Strong liquidity Near
    Current ratio ≥ 2× · 1.76×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Earnings stability Pass
    A profit every year (7-yr record) · no losses
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Pass
    Uninterrupted dividends · paid every year (7)
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth Pass
    Earnings +33% over the record · +60%
    What this means

    At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €0.44/share (latest year €0.46), the averaged base the calculator's gate runs on, and book value is €4.91/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2019–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 7 of 7
    What this means

    Never lost money over the record, the earnings stability Graham insisted on.

  • Operating margin 15% → 17% (3-yr avg ends)
    What this means

    Through the cycle the operating margin held roughly steady — about 15% early, 17% lately, median 17%.

  • Owner earnings growth +19%/yr
    What this means

    Owner earnings grew about 19% a year over the record.

  • Worst year 2019 · 11.6% op. margin
    What this means

    Stayed profitable even in its hardest year, the resilience that survives recessions.

  • Share count +2.1%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

  • Dividend record rising
    What this means

    Paid and raised the dividend across the record, the continuity Graham prized.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Dec 31, 2025

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets€943M
  • Cash & short-term investments€141M
  • Receivables€303M
  • Inventory€268M
  • Other current assets€231M
Current liabilities€536M
  • Accounts payable€342M
  • Other current liabilities€194M
Current ratio1.76×all current assets ÷ what's due · Graham looked for 2×
Quick ratio1.26×stricter: inventory excluded
Cash ratio0.26×strictest: cash alone against what's due
Working capital€407Mthe cushion left after near-term bills
Deeper floors
Tangible book value€1.4Bequity stripped of goodwill & intangibles
Net current asset value(€114M)Graham's net-net: current assets less all liabilities
Debt incl. operating leases€14M€14M of it operating leases
Deferred revenue€10Mcustomer cash collected before delivery; operating float

From the company's latest filing.

How the cash was used, 2019–2025

Over the record, the business generated €982M of operating cash; how management split it reads as a reinvestor, most operating cash is plowed back into the business.

  • Reinvested€1.5B · 153%
  • Dividends€83M · 8%
  • Returned to owners€83M

    16% of the owner earnings the business produced over the span, €83M as dividends and €0 as buybacks.

  • Source of funding−€601M

    Reinvestment and shareholder returns ran €601M beyond the operating cash the business generated, so the gap was financed off the balance sheet.

  • Net change in share count13.5%

    The diluted count rose from 241M to 273M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.

  • Dividend record€0.05/sh

    Paid in 7 of the years on record, the per-share dividend growing about 13% a year. It was never cut over the span.

  • Return on what it retained6%

    Of the earnings it kept rather than paid out (€715M over the span), annual owner earnings (first three years vs last three) grew €42M, so each retained €1 added about 0.06 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Inverting the record

Invert: instead of why Stevanato Group S.p.A. is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2019–2025.

1 of the 3 tests turned up something to look into; the other 2 came back clean.

  • Look hereDid the share count rise anyway?13.5%

    Diluted shares grew 13.5% over 2019–2025. Owners were diluted on net; each share owns less of the business than it did. Read the buyback line beside this one, not on its own.

And these came back clean
  • Is it less profitable than it was?
  • Did reported profit become cash?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

Peers, Medical Devices & Equipment

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
WSTWest Pharmaceutical$3.1B35%19.0%19%17%
ICUIICU Medical$2.2B37%2.0%5%5%
MSAMSA Safety Incorporated$1.9B45%13.2%13%11%
ITGRInteger Holdings$1.9B27%11.2%6%7%
MMSIMerit Medical Systems$1.5B45%6.2%4%7%
STVNStevanato Group S.p.A.€1.2B29%16.8%19%7%
UFPTUFP Technologies Inc.$603M25%11.4%12%8%
AORTArtivion Inc.$441M66%3.9%4%2%
Group median36%11.3%9%7%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the home-market price, not the US ADR quote. Stevanato Group S.p.A. reports in EUR, and every figure here (owner earnings, book value, the share count) is on that EUR, ordinary-share basis. Enter the price on the same basis: the local-exchange quote per ordinary share in EUR. A US ADR price in dollars bundles the ADR-to-ordinary ratio and the exchange rate, so it will not reconcile with these figures and would throw the multiple off.

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Stevanato Group S.p.A. has delivered.

Stevanato Group S.p.A.’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.

Through the cycle, Stevanato Group S.p.A. earns about €81M on its 6.8% median owner-earnings margin. This year’s 17.5% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.

Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’21→’25+24%/yr
Owner-earnings growth, delivered
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Free cash flow €22M on 303M shares outstanding, per the 20-F cover, as of 2025-12-31; net cash €141M. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. Capex (€264M) runs well above depreciation (€78M), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about €208M, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Stevanato Group S.p.A. (STVN), the owner's record," https://ownerscorecard.com/c/STVN, data as of 2026-07-09.

Manual order: ← STNG its page in the Manual SU →

Industry order: ← STE the Medical Devices & Equipment chapter SYK →